A ten-week, multicenter, randomised, double-blind, placebo-and active-controlled, parallel-group, flexible-dose study evaluating the efficacy, safety and tolerability of GSK372475 [NS 2359] or paroxetine compared to placebo in adult subjects diagnosed with major depressive disorder.

Trial Profile

A ten-week, multicenter, randomised, double-blind, placebo-and active-controlled, parallel-group, flexible-dose study evaluating the efficacy, safety and tolerability of GSK372475 [NS 2359] or paroxetine compared to placebo in adult subjects diagnosed with major depressive disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs NS 2359 (Primary) ; Paroxetine
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 May 2012 Results published in the Journal of Psychopharmacology.
    • 10 Dec 2009 Results presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology.
    • 23 Feb 2009 Endpoint 'Bech 6-item Scale a subscale of the HAM-D-17' has not been met in a comparison against placebo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top